Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has today announced that it has received a Clinical Trial Approval (CTA) from the UK’s regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer.
Soft Skills for Scientists: do you need to improve communication and productivity in your business? Workshops for professionals in science and technology this autumn. Discounts for Bionow members!
Orla surfaces have been used to promote myoblast cell differentiation in a study led by Prof Michelle Peckham of University of Leeds. Orla’s surfaces outperformed traditionally used gelatin coated glass coverslips in fusion and differentiation assays with three muscle cell lines.